wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 700.
1 2 3 4 5 ... 14 Next »

Medicine/Pharmacology - Life Sciences
17.01.2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy   EMA granted accelerate
Life Sciences - Computer Science/Telecom
11.01.2018
Blue Brain Nexus: an open-source tool for data-driven science
Knowledge sharing is an important driving force behind scientific progress. In an open-science approach, EPFL's Blue Brain Project has created and open sourced Blue Brain Nexus that allows the building of data integration platforms.
Medicine/Pharmacology - Life Sciences
09.01.2018
Novartis advances head-to-head superiority trials of Cosentyx versus Humira * and proposed biosimilar adalimumab**
SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS) EXCEED is the first head-to-head superiority trial versus Humira * in psoria
Medicine/Pharmacology - Life Sciences
03.01.2018
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K
Life Sciences - Medicine/Pharmacology
27.12.2017
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous-unemotional traits are linked to differences in brain structure in boys, but not girls. This reports a European research team led by the University of Basel and University of Basel Psychiatric Hospital in a study on brain development in 189 adolescents.
Medicine/Pharmacology - Life Sciences
21.12.2017
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC
Medicine/Pharmacology - Life Sciences
12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c
Medicine/Pharmacology - Life Sciences
12.12.2017
Medicine/Pharmacology - Life Sciences
11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.
Life Sciences - Environment/Sustainable Development
11.12.2017
Medicine/Pharmacology - Life Sciences
10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six
Life Sciences - Medicine/Pharmacology
08.12.2017
Acrobatic Duo in the Cells
Acrobatic Duo in the Cells
Just like an acrobatic duo, some proteins lend each other stability. Researchers at the Biozentrum of the University of Basel have discovered that the protein ‘Trigger factor' recognizes a partner by instable, flexible domains, to then together form a stable protein duo. The study has been published in the current issue of ‘Nature Communications'.
Medicine/Pharmacology - Life Sciences
07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi
Medicine/Pharmacology - Life Sciences
05.12.2017
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data.
Medicine/Pharmacology - Life Sciences
30.11.2017
Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Novartis' Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Unique Cosentyx (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis - Cosentyx results represent the first data on biologic use for up to 2.5 years in these hard-to-treat types of psoriasis , Results add to body of e
Medicine/Pharmacology - Life Sciences
29.11.2017
Innovation/Technology - Life Sciences
23.11.2017
Medicine/Pharmacology - Life Sciences
21.11.2017
Medicine/Pharmacology - Life Sciences
20.11.2017
Novartis drug Tasigna (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children   Approval builds on a series of Tasigna regulatory milestones, including addition of Treatment-free Remission (TFR) data to EU label for adults with Ph+ CML-CP   Demonstrates Novartis' continuing commitment to CML patients - Novartis announced today that the European Commission (EC) approved Tasigna (nilotinib
Medicine/Pharmacology - Life Sciences
14.11.2017
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively  Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to
Medicine/Pharmacology - Life Sciences
10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.
Medicine/Pharmacology - Life Sciences
08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e
Medicine/Pharmacology - Life Sciences
07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.
Medicine/Pharmacology - Life Sciences
06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica
Life Sciences - Medicine/Pharmacology
03.11.2017
Reading our brain chemistry
Reading our brain chemistry
Researchers at EPFL have developed a new device and analysis method that let doctors measure the neurochemicals in a patient's brain. The  Microsystems Laboratory 4 (LMIS4)'s system involves collecting microdroplets of cerebral fluid and analyzing them to obtain chemical data that can help doctors diagnose and treat neurodegenerative diseases.
Environment/Sustainable Development - Life Sciences
03.11.2017
Mapping Functional Diversity of Forests with Remote Sensing
Mapping Functional Diversity of Forests with Remote Sensing
Ecological studies have demonstrated positive relationships between plant diversity and ecosystem functioning. Forests with higher functional diversity are generally more productive and stable over long timescales than less diverse forests. Diverse plant communities show increased resource use efficiency and utilization, enhanced ecosystem productivity and stability and can better cope with changing environmental conditions - an insurance effect of biodiversity.
Life Sciences - Environment/Sustainable Development
02.11.2017
UZH Anthropologists Describe Third Orangutan Species
Two species of Indonesian orangutans had previously been officially described and recognized - the Pongo abelii , living on the island of Sumatra, and the Pongo pygmeaeus , endemic to Borneo. In 1997, researchers at the Australian National University discovered an isolated population of orangutans in Batang Toru, a region within the three Tapanuli districts in North Sumatra.
Life Sciences - Medicine/Pharmacology
02.11.2017
How Caries-Causing Bacteria Can Survive in Dental Plaque
How Caries-Causing Bacteria Can Survive in Dental Plaque
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One. Cariogenic bacteria live in biofilm and attack dental enamel by converting sugar and starch into acids that dissolve out calcium from the enamel.
Medicine/Pharmacology - Life Sciences
02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e
Medicine/Pharmacology - Life Sciences
01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL   Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl
Medicine/Pharmacology - Life Sciences
31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated
Life Sciences - Medicine/Pharmacology
30.10.2017
Important Mechanism of Epigenetic Gene Regulation Identified
DNA contains the blueprint of an entire organism. Based on the information in this blueprint, every cell knows what it must become and what function it must perform. Throughout the entire lifespan of an organism, the genetic information has to be read correctly to ensure that genes are active at the right time and in the right cells.
Medicine/Pharmacology - Life Sciences
28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.
Life Sciences
27.10.2017
Advanced artificial limbs mapped in the brain
Advanced artificial limbs mapped in the brain
EPFL scientists from the Center for Neuroprosthetics have used functional MRI to show how the brain re-maps motor and sensory pathways following targeted motor and sensory reinnervation (TMSR), a neuroprosthetic approach where residual limb nerves are rerouted towards intact muscles and skin regions to control a robotic limb.
Medicine/Pharmacology - Life Sciences
26.10.2017
Bacteria Have a Sense of Touch
Bacteria Have a Sense of Touch
Although bacteria have no sensory organs in the classical sense, they are still masters in perceiving their environment. A research group at the University of Basel's Biozentrum has now discovered that bacteria not only respond to chemical signals, but also possess a sense of touch. In their recent publication in "Science", the researchers demonstrate how bacteria recognize surfaces and respond to this mechanical stimulus within seconds.
Medicine/Pharmacology - Life Sciences
25.10.2017
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya (fingolimod) in pediatric MS will be presented for the first time   With 54 accepted abstracts, Novartis presence spans from new siponimod (BAF312) data in secondary progressive MS (SPMS) to innovative research on neurofilaments - a promising MS biomarker - Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at
Life Sciences
24.10.2017
High-Speed Locomotion Neurons Found in the Brainstem
High-Speed Locomotion Neurons Found in the Brainstem
A clearly defined subpopulation of neurons in the brainstem is essential to execute locomotion at high speeds. Interestingly, these high-speed neurons are intermingled with others that can elicit immediate stopping. How defined groups of brainstem neurons can regulate important aspects of full motor programs, reports a study by researchers of the Biozentrum at the University of Basel and the Friedrich Miescher Institute for Biomedical Research (FMI).
Life Sciences - Microtechnics/Electroengineering
20.10.2017
Embark on a cognitive revolution at EPFL
Use your brainwaves to control the workings of a machine and contribute to science at EPFL ArtLab's next art-science exhibition, "Mental Work" from October 27 th - February 11 th , 2018.
Medicine/Pharmacology - Life Sciences
16.10.2017
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to
Physics/Materials Science - Life Sciences
09.10.2017
Life Sciences
05.10.2017
Physics/Materials Science - Life Sciences
04.10.2017
Highlighting the significance of structural analysis of biomolecules
Highlighting the significance of structural analysis of biomolecules
The Nobel Prize in Chemistry 2017 has been awarded to Jacques Dubochet of Switzerland, U.S.-based German scientist Joachim Frank, and Richard Henderson of the United Kingdom for the development of structural analysis of single biological molecules by means of cryo-electron microscopy.
Life Sciences - Medicine/Pharmacology
03.10.2017
Clumps as temporary storage
Clumps as temporary storage
Researchers at ETH have discovered that the formation of protein aggregates in yeast cells is reversible. This casts new light on human diseases that can be attributed to certain protein aggregates. Protein aggregates have a bad reputation. A number of human diseases, especially those of the nervous system, such as Alzheimer's, Parkinson's, or amyotrophic lateral sclerosis (ALS), are due to the clumping of degenerate proteins in nerve cells, creating aggregates that the cells cannot dissolve.
Environment/Sustainable Development - Life Sciences
29.09.2017
5 professors appointed
At its meeting of 28 September 2017, the ETH Board appointed 5 new professors upon application of ETH Zurich President Lino Guzzella.
Medicine/Pharmacology - Life Sciences
28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch
1 2 3 4 5 ... 14 Next »